The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was supported by positive 1-year data from the phase 3 Pagoda study, in which Susvimo ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with diabetes. Susvimo, also ...

Digital healthcare provider, Notal Vision, announced that the results of a pivotal study evaluating the performance of an artificial intelligence ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize ...

In 2012, Dench first revealed that she had been diagnosed with age-related macular degeneration (AMD), a degenerative eye condition which is the biggest cause of sight loss in the UK, affecting ...

If left untreated, wet or late AMD can cause severe vision loss but it's difficult to predict how long that will take. It depends on many factors, such as the size of the deposits or abnormal blood ...